Although lung cancer cell lines demonstrate a decrease in KRAS levels, activation of the MAPK pathway kinases MEK1/2, ERK 1/2, and p90RSK is observed after treatment with the PCAIs [39, 43]. The gene discussed is MAP2K1; the disease is lung carcinoma.